

## **References**

- Alimova, I., Ng, J., Harris, P., Birks, D., Donson, A., Taylor, M. D., . . . Vibhakar, R. (2016). MPS1 kinase as a potential therapeutic target in medulloblastoma. *Oncology Reports, 36*(5), 2633-2640. doi:10.3892/or.2016.5085
- Angiolillo, A. L., Yu, A. L., Reaman, G., Ingle, A. M., Secola, R., & Adamson, P. C. (2009). A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: A Childrens Oncology Group report. *Pediatric Blood & Cancer, 53*(6), 978-983. doi:10.1002/pbc.22209
- Aref, S., Azmy, E., El-Bakry, K., Ibrahim, L., & Mabed, M. (2017). Prognostic impact of CD200 and CD56 expression in adult acute lymphoblastic leukemia patients. *Hematology, 1*-8. doi:10.1080/10245332.2017.1404276
- Barone, G., Tweddle, D., Shohet, J., Chesler, L., Moreno, L., Pearson, A., & Maerken, T. (2014). MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance. *Current Drug Targets, 15*(1), 114-123. doi:10.2174/13894501113149990194
- Barrett, D., Brown, V. I., Grupp, S. A., & Teachey, D. T. (2012). Targeting the PI3K/AKT/mTOR Signaling Axis in Children with Hematologic Malignancies. *Pediatric Drugs, 14*(5), 299-316. doi:10.1007/bf03262236
- Bavetsias, V., & Linardopoulos, S. (2015). Aurora Kinase Inhibitors: Current Status and Outlook. *Frontiers in Oncology, 5*. doi:10.3389/fonc.2015.00278
- Bax, D. A., Gaspar, N., Little, S. E., Marshall, L., Perryman, L., Regairaz, M., . . . Jones, C. (2009). EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines. *Clinical Cancer Research, 15*(18), 5753-5761. doi:10.1158/1078-0432.ccr-08-3210

- Becher, O. J., Peterson, K. M., Khatua, S., Santi, M. R., & Macdonald, T. J. (2008). IGFBP2 Is Overexpressed by Pediatric Malignant Astrocytomas and Induces the Repair Enzyme DNA-PK. *Journal of Child Neurology*, *23*(10), 1205-1213. doi:10.1177/0883073808321766
- Bell, J. B., Eckerdt, F. D., Alley, K., Magnusson, L. P., Hussain, H., Bi, Y., . . . Platanias, L. C. (2016). MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma. *Molecular Cancer Research*, *14*(10), 984-993. doi:10.1158/1541-7786.mcr-16-0172
- Bender, J. G., Yamashiro, D. J., & Fox, E. (2011). Clinical Development of VEGF Signaling Pathway Inhibitors in Childhood Solid Tumors. *The Oncologist*, *16*(11), 1614-1625. doi:10.1634/theoncologist.2011-0148
- Bhatia, S., Pavlick, A. C., Boasberg, P., Thompson, J. A., Mulligan, G., Pickard, M. D., . . . Hamid, O. (2016). A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma. *Investigational New Drugs*, *34*(4), 439-449. doi:10.1007/s10637-016-0348-5
- Birley, K., Chester, K., & Anderson, J. (2018). Antibody based therapy for childhood solid cancers. *Current Opinion in Chemical Engineering*, *19*, 153-162. doi:10.1016/j.coche.2018.01.005
- Bobola, M. S. (2005). O6-Methylguanine-DNA Methyltransferase, O6-Benzylguanine, and Resistance to Clinical Alkylators in Pediatric Primary Brain Tumor Cell Lines. *Clinical Cancer Research*, *11*(7), 2747-2755. doi:10.1158/1078-0432.ccr-04-2045
- Bonifant, C. L., Szoor, A., Torres, D., Joseph, N., Velasquez, M. P., Iwahori, K., . . . Gottschalk, S. (2016). CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia. *Molecular Therapy*, *24*(9), 1615-1626. doi:10.1038/mt.2016.116
- Bosse, K. R., Raman, P., Zhu, Z., Lane, M., Martinez, D., Heitzeneder, S., . . . Maris, J. M. (2017).

Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. *Cancer Cell*, 32(3). doi:10.1016/j.ccell.2017.08.003

Bouffet, E. (2007). Faculty of 1000 evaluation for Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: A report from the Childrens Oncology Group. *F1000 - Post-publication Peer Review of the Biomedical Literature*. doi:10.3410/f.1098180.554184

Bredel, C., Lassmann, S., Pollack, I., Knoth, R., Hamilton, R., Volk, B., . . . Bredel, M. (2005). DNA topoisomerase II $\alpha$  and Her-2/neu gene dosages in pediatric malignant gliomas. *International Journal of Oncology*. doi:10.3892/ijo.26.5.1187

Brown, V. I., Seif, A. E., Reid, G. S., Teachey, D. T., & Grupp, S. A. (2008). Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease. *Immunologic Research*, 42(1-3), 84-105. doi:10.1007/s12026-008-8038-9

Buontempo, F., Mccubrey, J. A., Orsini, E., Ruzzene, M., Cappellini, A., Lonetti, A., . . . Martelli, A. M. (2017). Therapeutic targeting of CK2 in acute and chronic leukemias. *Leukemia*, 32(1), 1-10. doi:10.1038/leu.2017.301

Butowski, N., Colman, H., Groot, J. F., Omuro, A. M., Nayak, L., Wen, P. Y., . . . Prados, M. (2015). Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: An Ivy Foundation Early Phase Clinical Trials Consortium phase II study. *Neuro-Oncology*, 18(4), 557-564. doi:10.1093/neuonc/nov245

Cahill, K. E., Morshed, R. A., & Yamini, B. (2015). Nuclear factor- $\kappa$ B in glioblastoma: Insights into regulators and targeted therapy. *Neuro-Oncology*, 18(3), 329-339. doi:10.1093/neuonc/nov265

Capitini, C. M., Otto, M., Desantes, K. B., & Sondel, P. M. (2014). Immunotherapy in pediatric malignancies: Current status and future perspectives. *Future Oncology*, 10(9), 1659-1678.

doi:10.2217/fon.14.62

- Cekanova, M., & Rathore, K. (2014). Animal models and therapeutic molecular targets of cancer: Utility and limitations. *Drug Design, Development and Therapy*, 1911. doi:10.2147/dddt.s49584
- Chaber, R., Fiszler-Maliszewska, L., Noworolska-Sauren, D., Kwasnicka, J., Wrobel, G., & Chybicka, A. (2013). The BCL-2 Protein in Precursor B Acute Lymphoblastic Leukemia in Children. *Journal of Pediatric Hematology/Oncology*, 35(3), 180-187. doi:10.1097/mpb.0b013e318286d29b
- Chang, C., & Hung, M. (2011). The role of EZH2 in tumour progression. *British Journal of Cancer*, 106(2), 243-247. doi:10.1038/bjc.2011.551
- Chao, M. P., Alizadeh, A. A., Tang, C., Jan, M., Weissman-Tsukamoto, R., Zhao, F., . . . Majeti, R. (2010). Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia. *Cancer Research*, 71(4), 1374-1384. doi:10.1158/0008-5472.can-10-2238
- Chen, H. X., & Sharon, E. (2013). IGF-1R as an anti-cancer target--trials and tribulations. *Chinese Journal of Cancer*, 32(5), 242-252. doi:10.5732/cjc.012.10263
- Chen, K. H., Wada, M., Pinz, K. G., Liu, H., Shuai, X., Chen, X., . . . Ma, Y. (2017). A compound chimeric antigen receptor strategy for targeting multiple myeloma. *Leukemia*, 32(2), 402-412. doi:10.1038/leu.2017.302
- Chen, Z., Wang, Z., Pang, J. C., Yu, Y., Bieberkehazi, S., Lu, J., . . . Yang, J. (2016). Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity. *Scientific Reports*, 6(1). doi:10.1038/srep29090
- Cheng, C., Pan, L., Dimitrakopoulou-Strauss, A., Schäfer, M., Wängler, C., Wängler, B., . . . Strauss, L. G. (2011). Comparison between 68Ga-bombesin (68Ga-BZH3) and the cRGD tetramer 68Ga-RGD4 studies in an experimental nude rat model with a neuroendocrine pancreatic tumor cell

line. *EJNMMI Research*, 1(1), 34. doi:10.1186/2191-219x-1-34

Chua, M., Ortega, C., Sheikh, A., Lee, M., Abdul-Rassoul, H., Hartshorn, K., & Dominguez, I. (2017).

CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target.

*Pharmaceuticals*, 10(4), 18. doi:10.3390/ph10010018

Ciccarelli, C., Vulcano, F., Milazzo, L., Gravina, G. L., Marampon, F., Macioce, G., . . . Zani, B. M.

(2016). Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro

radioresistance of embryonal rhabdomyosarcoma stem-like cell population. *Molecular Cancer*,

15(1). doi:10.1186/s12943-016-0501-y

Cloos, J., Roeten, M. S., Franke, N. E., Meerloo, J. V., Zweegman, S., Kaspers, G. J., & Jansen, G.

(2017). (Immuno)proteasomes as therapeutic target in acute leukemia. *Cancer and Metastasis*

*Reviews*, 36(4), 599-615. doi:10.1007/s10555-017-9699-4

Cruzeiro, G. A., Reis, M. B., Silveira, V. S., Lira, R. C., Jr, C. G., Neder, L., . . . Valera, E. T. (2018).

HIF1A is Overexpressed in Medulloblastoma and its Inhibition Reduces Proliferation and

Increases EPAS1 and ATG16L1 Methylation. *Current Cancer Drug Targets*, 18(3), 287-294.

doi:10.2174/1568009617666170315162525

D'Angelo, V., Iannotta, A., Ramaglia, M., Lombardi, A., Zarone, M. R., Desiderio, V., . . . Caraglia, M.

(2015). EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable

molecular target in combination treatment approaches. *Journal of Experimental & Clinical*

*Cancer Research*, 34(1). doi:10.1186/s13046-015-0191-0

Diede, S. J., Guenthoer, J., Geng, L. N., Mahoney, S. E., Marotta, M., Olson, J. M., . . . Tapscott, S. J.

(2009). DNA methylation of developmental genes in pediatric medulloblastomas identified by

denaturation analysis of methylation differences. *Proceedings of the National Academy of*

*Sciences*, 107(1), 234-239. doi:10.1073/pnas.0907606106

- Dienstmann, R., Rodon, J., Prat, A., Perez-Garcia, J., Adamo, B., Felip, E., . . . Taberero, J. (2013). Genomic aberrations in the FGFR pathway: Opportunities for targeted therapies in solid tumors. *Annals of Oncology*, *25*(3), 552-563. doi:10.1093/annonc/mdt419
- Dillon, L., & Miller, T. (2014). Therapeutic Targeting of Cancers with Loss of PTEN Function. *Current Drug Targets*, *15*(1), 65-79. doi:10.2174/1389450114666140106100909
- Dolman, M. E., Ploeg, I. V., Koster, J., Bate-Eya, L. T., Versteeg, R., Caron, H. N., & Molenaar, J. J. (2015). DNA-Dependent Protein Kinase As Molecular Target for Radiosensitization of Neuroblastoma Cells. *Plos One*, *10*(12). doi:10.1371/journal.pone.0145744
- Dupain, C., Harttrampf, A. C., Urbinati, G., Georger, B., & Massaad-Massade, L. (2017). Relevance of Fusion Genes in Pediatric Cancers: Toward Precision Medicine. *Molecular Therapy - Nucleic Acids*, *6*, 315-326. doi:10.1016/j.omtn.2017.01.005
- Dvorak, C. C., & Loh, M. L. (2014). Juvenile Myelomonocytic Leukemia: Molecular Pathogenesis Informs Current Approaches to Therapy and Hematopoietic Cell Transplantation. *Frontiers in Pediatrics*, *2*. doi:10.3389/fped.2014.00025
- Dworzak, M. N., Schumich, A., Printz, D., Potschger, U., Husak, Z., Attarbaschi, A., . . . Gardner, H. (2008). CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: Setting the stage for anti-CD20 directed immunotherapy. *Blood*, *112*(10), 3982-3988. doi:10.1182/blood-2008-06-164129
- Dyberg, C., Fransson, S., Andonova, T., Sveinbjörnsson, B., Lännerholm-Palm, J., Olsen, T. K., . . . Wickström, M. (2017). Rho-associated kinase is a therapeutic target in neuroblastoma. *Proceedings of the National Academy of Sciences*, *114*(32). doi:10.1073/pnas.1706011114
- Etchin, J., Berezovskaya, A., Conway, A. S., Galinsky, I. A., Stone, R. M., Baloglu, E., . . . Look, A. T. (2016). KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well

tolerated and highly active against AML blasts and leukemia-initiating cells. *Leukemia*, 31(1), 143-150. doi:10.1038/leu.2016.145

Ferrando, A. A. (2009). The role of NOTCH1 signaling in T-ALL. *Hematology*, 2009(1), 353-361. doi:10.1182/asheducation-2009.1.353

Ferraz-De-Souza, B., Lin, L., & Achermann, J. C. (2011). Steroidogenic factor-1 (SF-1, NR5A1) and human disease. *Molecular and Cellular Endocrinology*, 336(1-2), 198-205. doi:10.1016/j.mce.2010.11.006

Fisher, J., & Anderson, J. (2017). Adoptive T Cell Therapies for Children's Cancers. *Immunotherapy for Pediatric Malignancies*, 161-174. doi:10.1007/978-3-319-43486-5\_8

Folgiero, V., Goffredo, B. M., Filippini, P., Masetti, R., Bonanno, G., Caruso, R., . . . Rutella, S. (2013). Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia. *Oncotarget*, 5(8). doi:10.18632/oncotarget.1504

Gamberi, G., Cocchi, S., Benini, S., Magagnoli, G., Morandi, L., Kreshak, J., . . . Alberghini, M. (2011). Molecular Diagnosis in Ewing Family Tumors. *The Journal of Molecular Diagnostics*, 13(3), 313-324. doi:10.1016/j.jmoldx.2011.01.004

Gilbertson, R. J. (2005). ERBB2 in Pediatric Cancer: Innocent Until Proven Guilty. *The Oncologist*, 10(7), 508-517. doi:10.1634/theoncologist.10-7-508

Goethem, A. V., Yigit, N., Moreno-Smith, M., Vasudevan, S. A., Barbieri, E., Speleman, F., . . . Maerken, T. V. (2017). Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma. *Oncotarget*, 8(34). doi:10.18632/oncotarget.18982

Goldman, S., Onar-Thomas, A., Dunkel, I., & Hwang, E. (2017). Abstract CT051: Tumor treating fields in pediatric recurrent high-grade glioma and ependymoma. *Cancer Research*, 77(13 Supplement). doi:10.1158/1538-7445.am2017-ct051

- Gordon, M. S., Kato, R. M., Lansigan, F., Thompson, A. A., Wall, R., & Rawlings, D. J. (2000). Aberrant B cell receptor signaling from B29 (Igbeta , CD79b) gene mutations of chronic lymphocytic leukemia B cells. *Proceedings of the National Academy of Sciences*, 97(10), 5504-5509. doi:10.1073/pnas.090087097
- Goss, K. L., & Gordon, D. J. (2016). Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma. *Oncotarget*, 7(39). doi:10.18632/oncotarget.11416
- Grafone, T., Palmisano, M., Nicci, C., & Storti, S. (2012). An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: Biology and treatment. *Oncology Reviews*, 6(1), 8. doi:10.4081/oncol.2012.e8
- Greenall, S. A., Lim, Y. C., Mitchell, C. B., Ensbey, K. S., Stringer, B. W., Wilding, A. L., . . . Johns, T. G. (2017). Cyclin-dependent kinase 7 is a therapeutic target in high-grade glioma. *Oncogenesis*, 6(5). doi:10.1038/oncsis.2017.33
- Greuber, E. K., Smith-Pearson, P., Wang, J., & Pendergast, A. M. (2013). Role of ABL family kinases in cancer: From leukaemia to solid tumours. *Nature Reviews Cancer*, 13(8), 559-571. doi:10.1038/nrc3563
- Hahm, K. (1999). Correction: Repression of the gene encoding the TGF- $\beta$  type II receptor is a major target of the EWS-FLI1 oncoprotein. *Nature Genetics*, 23(4), 481-481. doi:10.1038/70611
- Hamilton, E., & Infante, J. R. (2016). Targeting CDK4/6 in patients with cancer. *Cancer Treatment Reviews*, 45, 129-138. doi:10.1016/j.ctrv.2016.03.002
- He, P., Jiang, S., Ma, M., Wang, Y., Li, R., Fang, F., . . . Zhang, Z. (2012). Trophoblast glycoprotein promotes pancreatic ductal adenocarcinoma cell metastasis through Wnt/planar cell polarity signaling. *Molecular Medicine Reports*, 12(1), 503-509. doi:10.3892/mmr.2015.3412

- Heldin, C. (2013). Targeting the PDGF signaling pathway in tumor treatment. *Cell Communication and Signaling*, *11*(1), 97. doi:10.1186/1478-811x-11-97
- Hensel, T., Giorgi, C., Schmidt, O., Calzada-Wack, J., Neff, F., Buch, T., . . . Richter, G. H. (2015). Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma. *Oncotarget*, *7*(2). doi:10.18632/oncotarget.6385
- Heske, C. M., Davis, M. I., Baumgart, J. T., Wilson, K., Gormally, M. V., Chen, L., . . . Thomas, C. J. (2017). Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. *Clinical Cancer Research*, *23*(23), 7301-7311. doi:10.1158/1078-0432.ccr-17-1121
- Hu, Y., Gu, X., Li, R., Luo, Q., & Xu, Y. (2010). Glycogen synthase kinase-3 $\beta$  inhibition induces nuclear factor- $\kappa$ B-mediated apoptosis in pediatric acute lymphocyte leukemia cells. *Journal of Experimental & Clinical Cancer Research*, *29*(1), 154. doi:10.1186/1756-9966-29-154
- Huang, S., & Yang, J. (2015). Targeting the Hedgehog Pathway in Pediatric Medulloblastoma. *Cancers*, *7*(4), 2110-2123. doi:10.3390/cancers7040880
- Huey, M., Minson, K., Earp, H., Deryckere, D., & Graham, D. (2016). Targeting the TAM Receptors in Leukemia. *Cancers*, *8*(11), 101. doi:10.3390/cancers8110101
- Hutter, S., Bolin, S., Weishaupt, H., & Swartling, F. (2017). Modeling and Targeting MYC Genes in Childhood Brain Tumors. *Genes*, *8*(4), 107. doi:10.3390/genes8040107
- Ichimura, K., Nishikawa, R., & Matsutani, M. (2012). Molecular markers in pediatric neuro-oncology. *Neuro-Oncology*, *14*(Suppl 4), Iv90-Iv99. doi:10.1093/neuonc/nos204
- Jackson, H. J., Rafiq, S., & Brentjens, R. J. (2016). Driving CAR T-cells forward. *Nature Reviews Clinical Oncology*, *13*(6), 370-383. doi:10.1038/nrcclinonc.2016.36
- Jatiani, S. S., Baker, S. J., Silverman, L. R., & Reddy, E. P. (2010). JAK/STAT Pathways in Cytokine

Signaling and Myeloproliferative Disorders: Approaches for Targeted Therapies. *Genes & Cancer*, 1(10), 979-993. doi:10.1177/1947601910397187

Jiang, Z., Wu, D., Lin, S., & Li, P. (2016). CD34 and CD38 are prognostic biomarkers for acute B lymphoblastic leukemia. *Biomarker Research*, 4(1). doi:10.1186/s40364-016-0080-5

Jin, Y., Zhou, J., Xu, F., Jin, B., Cui, L., Wang, Y., . . . Pan, J. (2016). Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia. *Journal of Clinical Investigation*, 126(10), 3961-3980. doi:10.1172/jci85239

Johnston, J., Navaratnam, S., Pitz, M., Maniate, J., Wiechec, E., Baust, H., . . . Los, M. (2006). Targeting the EGFR Pathway for Cancer Therapy. *Current Medicinal Chemistry*, 13(29), 3483-3492. doi:10.2174/092986706779026174

Jones, L., Carol, H., Evans, K., Richmond, J., Houghton, P. J., Smith, M. A., & Lock, R. B. (2016). A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program. *Leukemia*, 30(11), 2133-2141. doi:10.1038/leu.2016.192

Khan, K. H., Yap, T. A., Yan, L., & Cunningham, D. (2013). Targeting the PI3K-AKT-mTOR signaling network in cancer. *Chinese Journal of Cancer*, 32(5), 253-265. doi:10.5732/cjc.013.10057

Kieran, M. W. (2014). Targeting BRAF in Pediatric Brain Tumors. *American Society of Clinical Oncology Educational Book*, 34. doi:10.14694/edbook\_am.2014.34.e436

Kikuchi, K., Soundararajan, A., Zarzabal, L. A., Weems, C. R., Nelon, L. D., Hampton, S. T., . . . Keller, C. (2012). Protein kinase C iota as a therapeutic target in alveolar rhabdomyosarcoma. *Oncogene*, 32(3), 286-295. doi:10.1038/onc.2012.46

Knight, T., & Irving, J. A. (2014). Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting. *Frontiers in Oncology*, 4. doi:10.3389/fonc.2014.00160

- Kohashi, K., & Oda, Y. (2017). Oncogenic roles of SMARCB1/INI1 and its deficient tumors. *Cancer Science*, *108*(4), 547-552. doi:10.1111/cas.13173
- Kolb, E. A., Gorlick, R., Keir, S. T., Maris, J. M., Lock, R., Carol, H., . . . Smith, M. A. (2011). Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a  $\gamma$ -secretase inhibitor targeting notch signaling. *Pediatric Blood & Cancer*, *58*(5), 815-818. doi:10.1002/pbc.23290
- Kopp, L. M., & Katsanis, E. (2015). Targeted immunotherapy for pediatric solid tumors. *OncImmunology*, *5*(3). doi:10.1080/2162402x.2015.1087637
- Kupp, R., Shtayer, L., Tien, A., Szeto, E., Sanai, N., Rowitch, D., & Mehta, S. (2016). Lineage-Restricted OLIG2-RTK Signaling Governs the Molecular Subtype of Glioma Stem-like Cells. *Cell Reports*, *16*(11), 2838-2845. doi:10.1016/j.celrep.2016.08.040
- Kwiatkowski, N., Zhang, T., Rahl, P. B., Abraham, B. J., Reddy, J., Ficarro, S. B., . . . Gray, N. S. (2014). Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. *Nature*, *511*(7511), 616-620. doi:10.1038/nature13393
- Lammens, T., Swerts, K., Derycke, L., Craemer, A. D., Brouwer, S. D., Preter, K. D., . . . Laureys, G. (2012). N-Cadherin in Neuroblastoma Disease: Expression and Clinical Significance. *PLoS ONE*, *7*(2). doi:10.1371/journal.pone.0031206
- Levy, A. S., Roth, M., Patterson, N., Scott, E., Quispe-Tintaya, W., Ewart, M. R., . . . Montagna, C. (2016). Abstract 15: Target next sequencing profiling of pediatric solid tumors: Potential use for the identification of actionable mutations. *Clinical Cancer Research*, *22*(1 Supplement), 15-15. doi:10.1158/1557-3265.pmsclingen15-15
- Li, W., Tsen, F., Sahu, D., Bhatia, A., Chen, M., Multhoff, G., & Woodley, D. T. (2013). Extracellular Hsp90 (eHsp90) as the Actual Target in Clinical Trials. *International Review of Cell and*

*Molecular Biology*, 203-235. doi:10.1016/b978-0-12-407697-6.00005-2

- Li, Z., Li, X., Xu, L., Tao, Y., Yang, C., Chen, X., . . . Pan, J. (2017). Inhibition of neuroblastoma proliferation by PF-3758309, a small-molecule inhibitor that targets p21-activated kinase 4. *Oncology Reports*, 38(5), 2705-2716. doi:10.3892/or.2017.5989
- Linardic, C. M. (2008). PAX3–FOXO1 fusion gene in rhabdomyosarcoma. *Cancer Letters*, 270(1), 10-18. doi:10.1016/j.canlet.2008.03.035
- Linzey, J. R., Marini, B., Mcfadden, K., Lorenzana, A., Mody, R., Robertson, P. L., & Koschmann, C. (2017). Identification and targeting of an FGFR fusion in a pediatric thalamic “central oligodendroglioma”. *Npj Precision Oncology*, 1(1). doi:10.1038/s41698-017-0036-8
- Liu, C., Hsu, Y., Pan, P., Wu, M., Ho, C., Su, L., . . . Christiani, D. C. (2008). Maternal and offspring genetic variants of AKR1C3 and the risk of childhood leukemia. *Carcinogenesis*, 29(5), 984-990. doi:10.1093/carcin/bgn071
- Louissaint, A., Schafernak, K. T., Geyer, J. T., Kovach, A. E., Ghandi, M., Gratzinger, D., . . . Weinstock, D. M. (2016). Pediatric-type nodal follicular lymphoma: A biologically distinct lymphoma with frequent MAPK pathway mutations. *Blood*, 128(8), 1093-1100. doi:10.1182/blood-2015-12-682591
- Lowery, C. D., Vanwye, A. B., Dowless, M., Blosser, W., Falcon, B. L., Stewart, J., . . . Stancato, L. F. (2017). The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma. *Clinical Cancer Research*, 23(15), 4354-4363. doi:10.1158/1078-0432.ccr-16-2876
- Luedtke, D. A., Niu, X., Pan, Y., Zhao, J., Liu, S., Edwards, H., . . . Ge, Y. (2017). Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. *Signal Transduction and Targeted Therapy*, 2, 17012.

doi:10.1038/sigtrans.2017.12

Mansouri, S., & Zadeh, G. (2015). Neddylation in glioblastomas. *Neuro-Oncology*, *17*(10), 1305-1306.

doi:10.1093/neuonc/nov165

Marengo, B., Ciucis, C. G., Ricciarelli, R., Furfaro, A. L., Colla, R., Canepa, E., . . . Domenicotti, C.

(2013). P38MAPK inhibition: A new combined approach to reduce neuroblastoma resistance under etoposide treatment. *Cell Death & Disease*, *4*(4). doi:10.1038/cddis.2013.118

Matsuo, H., Nakamura, N., Tomizawa, D., Saito, A. M., Kiyokawa, N., Horibe, K., . . . Adachi, S.

(2016). CXCR4 Overexpression is a Poor Prognostic Factor in Pediatric Acute Myeloid Leukemia With Low Risk: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group. *Pediatric Blood & Cancer*, *63*(8), 1394-1399. doi:10.1002/pbc.26035

Maturu, P., Jones, D., Ruteshouser, E. C., Hu, Q., Reynolds, J. M., Hicks, J., . . . Overwijk, W. W.

(2017). Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Microenvironment and in Initiation and Progression of Wilms Tumor. *Neoplasia*, *19*(3), 237-249. doi:10.1016/j.neo.2016.07.009

Messerli, S. M., Hoffman, M. M., Gnimpieba, E. Z., & Bhardwaj, R. D. (2017). Therapeutic Targeting

of PTK7 is Cytotoxic in Atypical Teratoid Rhabdoid Tumors. *Molecular Cancer Research*, *15*(8), 973-983. doi:10.1158/1541-7786.mcr-16-0432

Mills, C. N., Newshean, S., Bonner, J. A., & Yang, E. S. (2011). Emerging Roles of Glycogen Synthase

Kinase 3 in the Treatment of Brain Tumors. *Frontiers in Molecular Neuroscience*, *4*. doi:10.3389/fnmol.2011.00047

Mody, R. J., Prensner, J. R., Everett, J., Parsons, D. W., & Chinnaiyan, A. M. (2016). Precision

medicine in pediatric oncology: Lessons learned and next steps. *Pediatric Blood & Cancer*, *64*(3). doi:10.1002/pbc.26288

- Morgan, G., & Johnsen, J. (2010). Might salicylate exert benefits against childhood cancer? *Ecancermedicalscience*. doi:10.3332/ecancer.2010.156
- Mueller, S., Hashizume, R., Yang, X., Kolkowitz, I., Olow, A. K., Phillips, J., . . . Haas-Kogan, D. A. (2013). Targeting Wee1 for the treatment of pediatric high-grade gliomas. *Neuro-Oncology*, *16*(3), 352-360. doi:10.1093/neuonc/not220
- Nagpal, P., Akl, M. R., Ayoub, N. M., Tomiyama, T., Cousins, T., Tai, B., . . . Suh, K. S. (2016). Pediatric Hodgkin lymphoma— biomarkers, drugs, and clinical trials for translational science and medicine. *Oncotarget*, *7*(41). doi:10.18632/oncotarget.11509
- Neff, J., & Chen, D. (2017). Pediatric Philadelphia-positive B lymphoblastic leukemia with CD56 expression and L2 morphology: Case report and review of the literature. *Human Pathology: Case Reports*, *8*, 9-12. doi:10.1016/j.ehpc.2016.12.002
- Noble, R. A., Bell, N., Blair, H., Sikka, A., Thomas, H., Phillips, N., . . . Wedge, S. R. (2017). Inhibition of monocarboxylate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma. *Haematologica*, *102*(7), 1247-1257. doi:10.3324/haematol.2016.163030
- Ohear, C., Heiber, J. F., Schubert, I., Fey, G., & Geiger, T. L. (2014). Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia. *Haematologica*, *100*(3), 336-344. doi:10.3324/haematol.2014.112748
- Orentas, R. J., Lee, D. W., & Mackall, C. (2012). Immunotherapy Targets in Pediatric Cancer. *Frontiers in Oncology*, *2*. doi:10.3389/fonc.2012.00003
- Padi, S. K., Luevano, L., Singh, N., Song, J., Pandey, R., Aster, J. C., . . . Kraft, A. (2017). Abstract 5820: Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset. *Cancer Research*, *77*(13 Supplement), 5820-5820. doi:10.1158/1538-

7445.am2017-5820

- Peri, A., Cellai, I., Benvenuti, S., Luciani, P., Baglioni, S., & Serio, M. (2008). PPAR $\gamma$  in Neuroblastoma. *PPAR Research*, 2008, 1-7. doi:10.1155/2008/917815
- Pinheiro, C., Granja, S., Longatto-Filho, A., Faria, A. M., Fragoso, M. C., Lovisoló, S. M., . . . Zerbini, M. C. (2017). GLUT1 expression in pediatric adrenocortical tumors: A promising candidate to predict clinical behavior. *Oncotarget*, 8(38). doi:10.18632/oncotarget.19135
- Porta, R., Borea, R., Coelho, A., Khan, S., Araújo, A., Reclusa, P., . . . Rolfo, C. (2017). FGFR a promising druggable target in cancer: Molecular biology and new drugs. *Critical Reviews in Oncology/Hematology*, 113, 256-267. doi:10.1016/j.critrevonc.2017.02.018
- Prasad, M. L., Vyas, M., Horne, M. J., Virk, R. K., Morotti, R., Liu, Z., . . . Nikiforov, Y. E. (2016). NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. *Cancer*, 122(7), 1097-1107. doi:10.1002/cncr.29887
- Prince, E., Shah, M., Venkataraman, S., Balakrishnan, I., Alimova, I., Harris, P., . . . Vibhakar, R. (2015). Mb-22 \* Checkpoint Kinase 1 Expression Is An Adverse Prognostic Marker And Therapeutic Target In Myc-Driven Medulloblastoma. *Neuro-Oncology*, 17(Suppl 3), Iii24-Iii24. doi:10.1093/neuonc/nov061.98
- Qiu, Q., Yang, C., Xiong, W., Tahiri, H., Payeur, M., Superstein, R., . . . Hardy, P. (2015). SYK is a target of lymphocyte-derived microparticles in the induction of apoptosis of human retinoblastoma cells. *Apoptosis*, 20(12), 1613-1622. doi:10.1007/s10495-015-1177-2
- Rausch, T., Jones, D., Zapatka, M., Stütz, A., Zichner, T., Weischenfeldt, J., . . . Korbel, J. (2012). Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations. *Cell*, 148(1-2), 59-71. doi:10.1016/j.cell.2011.12.013

#### References

Reynolds, P. A. (2003). Identification of a DNA-binding site and transcriptional target for the EWS-

WT1( KTS) oncoprotein. *Genes & Development*, 17(17), 2094-2107.

doi:10.1101/gad.1110703

Ricks, T. K., Chiu, H., Ison, G., Kim, G., Mckee, A. E., Kluetz, P., & Pazdur, R. (2015). Successes and Challenges of PARP Inhibitors in Cancer Therapy. *Frontiers in Oncology*, 5.

doi:10.3389/fonc.2015.00222

Rihacek, M., Bienertova-Vasku, J., Valik, D., Sterba, J., Pilatova, K., & Zdrzilova-Dubaska, L. (2015). B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia. *BioMed Research International*, 2015, 1-9. doi:10.1155/2015/792187

Rimkus, T., Carpenter, R., Qasem, S., Chan, M., & Lo, H. (2016). Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothed and GLI Inhibitors. *Cancers*, 8(2), 22.

doi:10.3390/cancers8020022

Rocha, J. C. (2005). Pharmacogenetics of outcome in children with acute lymphoblastic leukemia.

*Blood*, 105(12), 4752-4758. doi:10.1182/blood-2004-11-4544

Roth, M., Barris, D. M., Piperdi, S., Kuo, V., Everts, S., Geller, D., . . . Gorlick, R. (2015). Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma. *Pediatric Blood & Cancer*, 63(1), 32-38.

doi:10.1002/pbc.25688

Rovida, E., & Sbarba, P. D. (2015). Colony-Stimulating Factor-1 Receptor in the Polarization of Macrophages: A Target for Turning Bad to Good Ones? *Journal of Clinical & Cellular Immunology*, 06(06). doi:10.4172/2155-9899.1000379

Sala, A. (2015). Editorial: Targeting MYCN in Pediatric Cancers. *Frontiers in Oncology*, 4.

doi:10.3389/fonc.2014.00330

Saletta, F., Wadham, C., Ziegler, D. S., Marshall, G. M., Haber, M., Mccowage, G., . . . Byrne, J. A.

- (2014). Molecular profiling of childhood cancer: Biomarkers and novel therapies. *BBA Clinical*, *1*, 59-77. doi:10.1016/j.bbacli.2014.06.003
- Shaffer, D. R., Savoldo, B., Yi, Z., Chow, K. K., Kakarla, S., Spencer, D. M., . . . Gottschalk, S. (2011). T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. *Blood*, *117*(16), 4304-4314. doi:10.1182/blood-2010-04-278218
- Shalabi, H., Angiolillo, A., & Fry, T. J. (2015). Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia. *Frontiers in Pediatrics*, *3*. doi:10.3389/fped.2015.00080
- Shukla, N., Ameer, N., Yilmaz, I., Nafa, K., Lau, C., Marchetti, A., . . . Ladanyi, M. (2011). Oncogene Mutation Profiling of Pediatric Solid Tumors Reveals Significant Subsets of Embryonal Rhabdomyosarcoma and Neuroblastoma with Mutated Genes in Growth Signaling Pathways. *Clinical Cancer Research*, *18*(3), 748-757. doi:10.1158/1078-0432.ccr-11-2056
- Siegel, P., R., A., & M. (2013). Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer. *OncoTargets and Therapy*, 839. doi:10.2147/ott.s44906
- Slany, R. K. (2016). The molecular mechanics of mixed lineage leukemia. *Oncogene*, *35*(40), 5215-5223. doi:10.1038/onc.2016.30
- Smith, K. M., Fagan, P. C., Pomari, E., Germano, G., Frasson, C., Walsh, C., . . . Li, G. (2017). Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3 – Positive Acute Myeloid Leukemia. *Molecular Cancer Therapeutics*, *17*(2), 455-463. doi:10.1158/1535-7163.mct-17-0419
- Stanton, R. A., Gernert, K. M., Nettles, J. H., & Aneja, R. (2011). ChemInform Abstract: Drugs that Target Dynamic Microtubules: A New Molecular Perspective. *ChemInform*, *42*(30). doi:10.1002/chin.201130277

- Stegmaier, S., Leuschner, I., Poremba, C., Ladenstein, R., Kazanowska, B., Ljungman, G., . . . Koscielniak, E. (2016). The prognostic impact of SYT-SSX fusion type and histological grade in pediatric patients with synovial sarcoma treated according to the CWS (Cooperative Weichteilsarkom Studie) trials. *Pediatric Blood & Cancer*, *64*(1), 89-95.  
doi:10.1002/pbc.26206
- Steinbach, D. (2006). Identification of a Set of Seven Genes for the Monitoring of Minimal Residual Disease in Pediatric Acute Myeloid Leukemia. *Clinical Cancer Research*, *12*(8), 2434-2441.  
doi:10.1158/1078-0432.ccr-05-2552
- Sun, W., Gaynon, P. S., Spoto, R., & Wayne, A. S. (2015). Improving access to novel agents for childhood leukemia. *Cancer*, *121*(12), 1927-1936. doi:10.1002/cncr.29267
- Takagi, M., Yoshida, M., Nemoto, Y., Tamaichi, H., Tsuchida, R., Seki, M., . . . Takita, J. (2017). Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor. *JNCI: Journal of the National Cancer Institute*, *109*(11). doi:10.1093/jnci/djx062
- Testa, U., Pelosi, E., & Frankel, A. (2014). CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. *Biomarker Research*, *2*(1), 4. doi:10.1186/2050-7771-2-4
- Theisen, E. R., Pishas, K. I., Saund, R. S., & Lessnick, S. L. (2016). Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting. *Oncotarget*, *7*(14).  
doi:10.18632/oncotarget.7124
- Thomaz, A., Jaeger, M., Buendia, M., Bambini-Junior, V., Gregianin, L. J., Brunetto, A. L., . . . Roesler, R. (2015). BDNF/TrkB Signaling as a Potential Novel Target in Pediatric Brain Tumors: Anticancer Activity of Selective TrkB Inhibition in Medulloblastoma Cells. *Journal of Molecular Neuroscience*, *59*(3), 326-333. doi:10.1007/s12031-015-0689-0
- Tp, T. A. (2015). Targeted Therapy for MAPK Alterations in Pediatric Gliomas. *Brain Disorders*

*& Therapy, S2*. doi:10.4172/2168-975x.s2-005

Tsuruta, T., Aihara, Y., Kanno, H., Funase, M., Murayama, T., Osawa, M., . . . Okada, Y. (2011).

Shared molecular targets in pediatric gliomas and ependymomas. *Pediatric Blood & Cancer, 57*(7), 1117-1123. doi:10.1002/pbc.23009

Tyner, J. W., Jemal, A. M., Thayer, M., Druker, B. J., & Chang, B. H. (2011). Targeting survivin and

p53 in pediatric acute lymphoblastic leukemia. *Leukemia, 26*(4), 623-632.

doi:10.1038/leu.2011.249

Uckun, F. M., & Qazi, S. (2014). SYK as a New Therapeutic Target in B-Cell Precursor Acute

Lymphoblastic Leukemia. *Journal of Cancer Therapy, 05*(01), 124-131.

doi:10.4236/jct.2014.51015

Uckun, F., & D. (2013). Novel Bruton's tyrosine kinase inhibitors currently in development.

*Oncotargets and Therapy, 161*. doi:10.2147/ott.s33732

Vella, S., Conaldi, P. G., Florio, T., & Pagano, A. (2016). PPAR Gamma in Neuroblastoma: The

Translational Perspectives of Hypoglycemic Drugs. *PPAR Research, 2016*, 1-10.

doi:10.1155/2016/3038164

Velpula, K. K., Guda, M. R., Sahu, K., Tuszyński, J., Asuthkar, S., Bach, S. E., . . . Tsung, A. J. (2017).

Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma.

*Oncotarget, 8*(22). doi:10.18632/oncotarget.16767

Venneti, S., & Huse, J. T. (2015). The Evolving Molecular Genetics of Low-grade Glioma. *Advances In*

*Anatomic Pathology, 22*(2), 94-101. doi:10.1097/pap.0000000000000049

Vonderheide, R. H. (2007). Prospect of Targeting the CD40 Pathway for Cancer Therapy. *Clinical*

*Cancer Research, 13*(4), 1083-1088. doi:10.1158/1078-0432.ccr-06-1893

Wang, X., Haswell, J. R., & Roberts, C. W. (2013). Molecular Pathways: SWI/SNF (BAF) Complexes

Are Frequently Mutated in Cancer--Mechanisms and Potential Therapeutic Insights. *Clinical Cancer Research*, 20(1), 21-27. doi:10.1158/1078-0432.ccr-13-0280

Ward, A. F., Braun, B. S., & Shannon, K. M. (2012). Targeting oncogenic Ras signaling in hematologic malignancies. *Blood*, 120(17), 3397-3406. doi:10.1182/blood-2012-05-378596

Waters, A. M., Stafman, L. L., Garner, E. F., Mruthyunjappa, S., Stewart, J. E., Mroczek-Musulman, E., & Beierle, E. A. (2016). Targeting Focal Adhesion Kinase Suppresses the Malignant Phenotype in Rhabdomyosarcoma Cells. *Translational Oncology*, 9(4), 263-273. doi:10.1016/j.tranon.2016.06.001

Weber, A. M., & Ryan, A. J. (2015). ATM and ATR as therapeutic targets in cancer. *Pharmacology & Therapeutics*, 149, 124-138. doi:10.1016/j.pharmthera.2014.12.001

West, A. C., & Johnstone, R. W. (2014). New and emerging HDAC inhibitors for cancer treatment. *Journal of Clinical Investigation*, 124(1), 30-39. doi:10.1172/jci69738

Wetmore, C., Boyett, J., Li, S., Lin, T., Bendel, A., Gajjar, A., & Orr, B. A. (2015). Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children. *Neuro-Oncology*, 17(6), 882-888. doi:10.1093/neuonc/nov017

Winde, C. M., Veenbergen, S., Young, K. H., Xu-Monette, Z. Y., Wang, X., Xia, Y., . . . Spriel, A. B. (2016). Tetraspanin CD37 protects against the development of B cell lymphoma. *Journal of Clinical Investigation*, 126(2), 653-666. doi:10.1172/jci81041

Winters, A. C., & Bernt, K. M. (2017). MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches. *Frontiers in Pediatrics*, 5. doi:10.3389/fped.2017.00004

Wise, D. R., & Thompson, C. B. (2010). Glutamine addiction: A new therapeutic target in cancer. *Trends in Biochemical Sciences*, 35(8), 427-433. doi:10.1016/j.tibs.2010.05.003

Witt, H., Mack, S., Ryzhova, M., Bender, S., Sill, M., Isserlin, R., . . . Pfister, S. (2011). Delineation of

Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa Ependymoma. *Cancer Cell*, 20(2), 143-157. doi:10.1016/j.ccr.2011.07.007

Wong, M., Tee, A., Milazzo, G., Bell, J., Hüttelmaier, S., Polly, P., . . . Liu, T. (2017). Abstract LB-080: The histone methyltransferase DOT1L promotes neuroblastoma by regulating gene transcription. *Cancer Research*, 77(13 Supplement). doi:10.1158/1538-7445.am2017-lb-080

Yan, S., Li, Z., & Thiele, C. J. (2013). Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo. *Oncotarget*, 4(3). doi:10.18632/oncotarget.930

Yang, H., Ye, D., Guan, K., & Xiong, Y. (2012). IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives. *Clinical Cancer Research*, 18(20), 5562-5571. doi:10.1158/1078-0432.ccr-12-1773

Ye, M., Zhang, X., Li, N., Zhang, Y., Jing, P., Chang, N., . . . Zhang, J. (2016). ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance. *Oncotarget*, 7(11). doi:10.18632/oncotarget.6935

Yoon, K. J., & Danks, M. K. (2009). Cell adhesion molecules as targets for therapy of neuroblastoma. *Cancer Biology & Therapy*, 8(4), 306-311. doi:10.4161/cbt.8.4.7446

Yuen, B., & Knoepfler, P. (2013). Histone H3.3 Mutations: A Variant Path to Cancer. *Cancer Cell*, 24(5), 567-574. doi:10.1016/j.ccr.2013.09.015

Zage, P. E., Nolo, R., Fang, W., Stewart, J., Garcia-Manero, G., & Zweidler-Mckay, P. A. (2011). Notch pathway activation induces neuroblastoma tumor cell growth arrest. *Pediatric Blood & Cancer*, 58(5), 682-689. doi:10.1002/pbc.23202

Zhang, J., Li, D., Lang, L., Zhu, Z., Wang, L., Wu, P., . . . Chen, X. (2015). <sup>68</sup>Ga-NOTA-Aca-BBN(7-14) PET/CT in Healthy Volunteers and Glioma Patients. *Journal of Nuclear Medicine*, 57(1), 9-

14. doi:10.2967/jnumed.115.165316

Zhao, X., Arca, D. D., Lim, W. K., Brahmachary, M., Carro, M. S., Ludwig, T., . . . Lasorella, A.

(2009). The N-Myc-DLL3 Cascade Is Suppressed by the Ubiquitin Ligase Huwe1 to Inhibit Proliferation and Promote Neurogenesis in the Developing Brain. *Developmental Cell*, 17(2), 210-221. doi:10.1016/j.devcel.2009.07.009

Zhou, Z., Luther, N., Ibrahim, G. M., Hawkins, C., Vibhakar, R., Handler, M. H., & Souweidane, M. M.

(2012). B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma. *Journal of Neuro-Oncology*, 111(3), 257-264. doi:10.1007/s11060-012-1021-2